A sustainable synthesis of the SARS-CoV-2 M(pro) inhibitor nirmatrelvir, the active ingredient in Paxlovid

Pfizer’s drug for the treatment of patients infected with COVID-19, Paxlovid, contains most notably nirmatrelvir, along with ritonavir. Worldwide demand is projected to be in the hundreds of metric tons per year, to be produced by several generic drug manufacturers. Here we show a 7-step, 3-pot synt...

Descripción completa

Detalles Bibliográficos
Autores principales: Kincaid, Joseph R. A., Caravez, Juan C., Iyer, Karthik S., Kavthe, Rahul D., Fleck, Nico, Aue, Donald H., Lipshutz, Bruce H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685088/
https://www.ncbi.nlm.nih.gov/pubmed/36465589
http://dx.doi.org/10.1038/s42004-022-00758-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685088/
https://www.ncbi.nlm.nih.gov/pubmed/36465589
http://dx.doi.org/10.1038/s42004-022-00758-5

Ejemplares similares